Journal
CLINICAL RHEUMATOLOGY
Volume 42, Issue 1, Pages 83-92Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-022-06373-y
Keywords
Biomarker; Kidney fibrosis; Lupus nephritis; Monocyte chemoattractant protein; Systemic lupus erythematosus
Categories
Ask authors/readers for more resources
This study aimed to assess the performance of uMCP-1 and its association with response to therapy and kidney function in LN patients. The results showed that urine MCP-1 levels were significantly higher in patients with active LN compared to those with chronic LN. Additionally, uMCP-1 played an important role in predicting treatment response and kidney function loss.
Objectives The present study aims to assess the course of uMCP-1 and its association with response to therapy and long-term kidney function in a prospective cohort of adults who received a kidney biopsy for suspicion of active lupus nephritis (LN). Methods Subjects were segregated into a histologically active LN group and a histologically chronic LN group. Both groups were followed for > = 36 months and urine were collected at flare, 3, 6, and 12 months of follow-up. The association between the course of uMCP-1, response to treatment, and progression to 30% loss of the eGFR was evaluated by linear mixed models for repeated measures. Results A kidney biopsy was performed on 125 subjects. In 114, the report was consistent with histologically active LN; in 11, with histologically chronic LN. Urine MCP-1 levels were significantly higher in the active LN than in the chronic LN group. Urine MCP-1 levels correlated with the histological findings of cellular crescents, endocapillary hypercellularity, interstitial inflammation, glomerular sclerosis, interstitial fibrosis, and tubular atrophy. The mean estimates of uMCP-1 at flare were higher in the non-response group than in the complete response group, and decreased in the complete/partial response groups by the third month, while they remained elevated in the non-response group. The mean estimates for uMCP-1 were higher at LN flare and remained elevated in patients who progressed to loss of 30% of the eGFR, while they decreased in patients with stable kidney function. Conclusion The first-year course of uMCP-1 is associated with response to therapy and kidney survival in LN.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available